CIK 0001818794
- Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 364883909
- Phone
- +1 781-786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $421,679
- in 7 filings, $422K under 10b5-1 plans
Net −$381,679. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-20 | Scalzo Richard William | Sale | −367 | $15.61 | $6K | 11,098 |
| 2021-09-20 | McNeill Jonathan | Sale | −545 | $15.61 | $9K | 36,365 |
| 2021-09-20 | Brumm Joshua T | Sale | −3,425 | $15.61 | $53K | 103,602 |
| 2021-09-20 | Beskrovnaya Oxana Chief Scientific Officer | Sale | −617 | $15.61 | $10K | 18,672 |
| 2021-07-13 | Atlas Venture Fund XI, L.P. 10% owner | Other disposition | −814,013 | 7,326,117 | ||
| 2021-07-10 | McNeill Jonathan | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2021-06-02 | Beskrovnaya Oxana Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2021-05-26 | Stehman-Breen Catherine Director | Grant or award · Stock Option (right to buy) | +19,596 | 19,596 | ||
| 2021-05-26 | Kersten Dirk Director | Grant or award · Stock Option (right to buy) | +19,596 | 19,596 | ||
| 2021-05-26 | Klein Lawrence Otto Director | Grant or award · Stock Option (right to buy) | +19,596 | 19,596 | ||
| 2021-05-26 | HURWITZ EDWARD Director | Grant or award · Stock Option (right to buy) | +19,596 | 19,596 | ||
| 2021-05-26 | Rhodes Jason P Director | Grant or award · Stock Option (right to buy) | +19,596 | 19,596 | ||
| 2021-05-26 | Lubner David Charles Director | Grant or award · Stock Option (right to buy) | +19,596 | 19,596 | ||
| 2021-03-02 | Farwell Wildon Chief Medical Officer | Grant or award | +50,000 | 50,000 | ||
| 2021-03-02 | Farwell Wildon Chief Medical Officer | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2020-09-21 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Conversion | +2,145,045 | 2,145,045 | ||
| 2020-09-21 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Purchase | +660,000 | $19.00 | $12.5M | 2,805,045 |
| 2020-09-21 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Conversion · Series B Preferred Stock | −7,114,905 | 0 | ||
| 2020-09-21 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion | +4,614,943 | 4,614,943 | ||
| 2020-09-21 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion | +245,279 | 245,279 |
Page 37 of 41 · 818 trades